This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus.

AU TGA pregnancy category: A
US FDA pregnancy category: C

Animal studies have revealed evidence of teratogenicity (cleft palate with/without hare lip, exencephaly, monophthalmia, shortened right forearm with bilateral wrist joint contracture, vertebral column abnormalities, including minor abnormalities of the cervical vertebra) when given high doses during pregnancy. A slight but not significant (P greater than 0.05) increase in fetal mortality, decrease in fertility, and decrease in litter size were observed. There are no controlled data in human pregnancy.

AU TGA pregnancy category A: Drugs which have been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the fetus having been observed.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

The WHO recommends stopping or changing the drug (if possible) in breastfed infants who develop significant jaundice. Artificial/formula feedings should be considered if this is not possible.

Benefit should outweigh risk.

Excreted into human milk: Yes

Comments:
-The WHO considers this drug compatible with breastfeeding; breastfed infants should be monitored for jaundice.
-The American Academy of Pediatrics considers this drug compatible with breastfeeding.
-The US Centers for Disease Control and Prevention, Infectious Diseases Society of America, American Thoracic Society, and the National Foundation for Infectious Diseases recommend that breastfeeding not be discouraged in women taking this drug.

See references